In this regular feature on Breakthroughs, we highlight some of the most interesting reads in global health research from the past week.
In this regular feature on Breakthroughs, we highlight some of the most interesting reads in global health research from the past week.
In this regular feature on Breakthroughs, we highlight some of the most interesting reads in global health research from the past week.
In this regular feature on Breakthroughs, we highlight some of the most interesting reads in global health research from the past week.
On February 15, President Trump signed into law a bipartisan spending bill—averting another partial government shutdown and ensuring full-year funding for the government for the remainder of fiscal year 2019. The months-long saga ended with some great news for global health and research and development.
As the partial government shutdown stretches into a fifth week – the longest in United States history – news of its impact on agencies essential to global health broadly, and research and development in particular, is taking clearer shape.
In this regular feature on Breakthroughs, we highlight some of the most interesting reads in global health research from the past week.
On Tuesday, the Trump Administration released its full fiscal year 2018 budget proposal. This budget proposes significant cuts to programs that support global health and medical research at the National Institutes of Health, Centers for Disease Control and Prevention, and the US Agency for International Development.
What global health R&D advocates need to know about the FY2017 budget agreement.
What global health advocates need to know about the President's "skinny" budget.
In this regular feature on Breakthroughs, we highlight some of the most interesting reads in global health research from the past week.
In this regular feature on Breakthroughs, we highlight some of the most interesting reads in global health research from the past week.
In this regular feature on Breakthroughs, we highlight the most promising Zika virus vaccine, drug, and diagnostic candidates as well as vector control approaches.
In this regular feature on Breakthroughs, we highlight some of the most interesting reads in global health research from the past week.
After four successful Phase 3 clinical trials enrolling more than 3,500 patients in 18 countries, the European Medicines Agency (EMA) has granted Pyramax® Granules, a pediatric malaria medicine, a positive opinion under Article 58—a mechanism through which the EMA reviews and issues a scientific opinion on products that are not intended for use in Europe.
Dr. Robert Gallo co-discovered the HIV virus and subsequently led the development of the first HIV/AIDS blood test.
A new study conducted by the Malaria Genomic Epidemiology Network (MalariaGEN)—a community of researchers across malaria-endemic regions—reveals a formerly unknown genetic variations that make people less susceptible to malaria.
The US Department of Health and Human Services (HHS) is partnering with New York–based Regeneron Pharmaceuticals, Inc. for the development of an Ebola treatment.
The US Department of Health and Human Services (HHS) announced last week a partnership with pharmaceutical company AstraZeneca for the research and development (R&D) of antibiotics.
Pharmaceutical company AbbVie is paying United Therapeutics US$350 million for its priority review voucher (PRV)—which expedites the US Food and Drug Administration’s (FDA) review of a product by four months—and EP Vantage speculates on their motive.
The US Food and Drug Administration (FDA) approved the first 3D-printed drug last week, paving the way for the technology to be used to customize medical care to individual patients.
Later this year, French pharmaceutical company Sanofi plans to launch a vaccine for dengue fever, the first on the market for an infection for which nearly half of the world’s population is at risk.
A new study published in PLOS Medicine indicates that multi-drug resistant tuberculosis (TB) is less contagious than drug-susceptible TB.
The zoonotic Middle East Respiratory Syndrome (MERS), which World Health Organization (WHO) Director-General Dr. Margaret Chan called “a threat to the entire world” has spread to South Korea. More than 100 cases and 10 deaths have been reported, making it the largest outbreak outside of the Arabian Peninsula.
The French pharmaceutical company Sanofi purchased a priority review voucher (PRV)—which entitles the owner to an expedited review of a future product by the US Food and Drug Administration (FDA)—for US$245 million last week.
Last week, the House Energy and Commerce Committee unanimously voted to approve the 21st Century Cures Act—a bill that aims to speed the development, approval, and introduction of new health technologies.
United States Representatives Jim Cooper (D-TN) and Cynthia Loomis (R-WO) introduced the Research for All Act last week which calls for the inclusion of more women in clinical trials for products submitted for US Food and Drug Administration (FDA) approval.
India is expected to add all of the drugs currently used in the government’s HIV/AIDS and tuberculosis (TB) control programs to its list of essential medicines within the next six months.
In this regular feature on Breakthroughs, we highlight some of the most interesting reads in global health research from the past week.
In this regular feature on Breakthroughs, we highlight some of the most interesting reads in global health research from the past week.
In this regular feature on Breakthroughs, we highlight some of the most interesting reads in global health research from the past week.
In this regular feature on Breakthroughs, we highlight some of the most interesting reads in global health research from the past week.
In this regular feature on Breakthroughs, we highlight some of the most interesting reads in global health research from the past week.
As the DC summer kicks into full swing, Congress has had a busy month moving forward fiscal year (FY) 2015 funding legislation for a variety of government programs including global health research and development (R&D).
Recently, there has been a surge of interest in evaluating progress made on the 2012 President’s Council of Advisors on Science and Technology’s (PCAST) recommendations that aim to accelerate research and development (R&D) of new therapeutics.
In this regular feature on Breakthroughs, we highlight some of the most interesting reads in global health research from the past week.
As more detailed information about the President’s fiscal year (FY) 2015 budget requests to Congress is released, the results continue to be a mixed bag for global health research and development (R&D).
Yesterday, the White House released President Obama’s much-anticipated budget request for fiscal year (FY) 2015.
As 2014 gets into full swing, the GHTC is looking ahead to many exciting developments on both the global health research and development (R&D) and policy landscapes:
In an increasingly rare show of bipartisanship, Congress has moved forward an appropriations agreement that should finally settle the issue of fiscal year (FY) 2014 funding levels.
In the past, the United States has contributed to important breakthroughs in global health—from the eradication of smallpox to a 74 percent drop in measles deaths worldwide.
In this guest post, Tricia Aung—the GHTC’s regulatory associate—writes about a new database that provides easy access to information on global health regulatory information.
The GHTC has long stressed that the US Food and Drug Administration (FDA) plays a critical part in efforts to improve global public health.
As we discussed yesterday, lawmakers in the House and Senate have been busy with several pieces of legislation that would fund global health and research efforts across the federal government.